Alaunos Therapeutics Price to Free Cash Flow Ratio 2010-2024 | TCRT

Alaunos Therapeutics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Alaunos Therapeutics Price to Free Cash Flow Ratio 2010-2024 | TCRT

Alaunos Therapeutics price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$74.8B
Chugai Pharmaceutical (CHGCY)$70.2B
Takeda Pharmaceutical (TAK)$41.1B
Sandoz Group AG (SDZNY)$19.6B
Merck (MKKGY)$18.8B
Astellas Pharma (ALPMY)$17.3B
United Therapeutics (UTHR)$16B
Neurocrine Biosciences (NBIX)$14.5B
Summit Therapeutics (SMMT)$14B
Shionogi (SGIOY)$12.1B
Orion OYJ (ORINY)$7.2B
Stevanato Group S.p.A (STVN)$6.9B
Madrigal Pharmaceuticals (MDGL)$6.4B
Corcept Therapeutics (CORT)$5.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Grifols, S.A (GRFS)$5B
Ionis Pharmaceuticals (IONS)$5B
Crinetics Pharmaceuticals (CRNX)$3.5B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Recursion Pharmaceuticals (RXRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.2B
Soleno Therapeutics (SLNO)$2B
Centessa Pharmaceuticals (CNTA)$2B
Hypermarcas (HYPMY)$1.9B
Indivior (INDV)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Evotec AG (EVO)$1.5B
Dyne Therapeutics (DYN)$1.4B
Xencor (XNCR)$1.3B